肿瘤及血液病患者血清sTRAIL表达及与IL-6和Hepcidin水平的相关性研究  

Study of the Expression of the Serum sTRAIL,and Its Correlation with Levels of Serum IL-6 and Hepcidin in the Patients with the Tumor and Hematological Diseases

作　　者：王秋云 严敏[1] 程珍 潘湘涛[1] WANG Qiu-yun;YAN Min;CHENG Zhen;PAN Xiang-tao(Taicang Hospital Affiliated to Suzhou University,Jiangsu Suzhou 215400,China)

机构地区：[1]苏州大学附属太仓医院,江苏苏州215400

出　　处：《现代检验医学杂志》2021年第1期58-60,64,共4页Journal of Modern Laboratory Medicine

摘　　要：目的研究肿瘤及血液病患者血清可溶性肿瘤坏死因子相关凋亡诱导配体(sTRAIL)表达,以及与白介素-6(IL-6)和铁调素(Hepc)表达的相关性及临床意义。方法2018年8月~2019年6月住院患者34例(18例肿瘤和16例血液病)及17例健康志愿者分别应用酶联免疫吸附法检测血清sTRAIL和Hepc,应用电化学发光法检测血清IL-6和SF,并分析其表达特点和相关关系。结果①肿瘤组和血液病组的sTRAIL水平分别为357.97±101.9 pg/ml和297.44±78.7pg/ml,均明显高于对照组的150.74±43.1pg/ml(F=31.53,P<0.01);Hepc分别为61.16±19.6μg/L和67.54±19.5μg/L,均明显高于对照组的34.78±11.9μg/L(F=16.74,P<0.01);IL-6分别为4.60±3.14mg/ml和12.49±11.69mg/ml,均明显高于对照组的1.66±0.28mg/ml(F=5.69,P<0.01)。②肿瘤组和血液病组的Hb分别为112.72±20.4g/L和76.31±27.4g/L,均明显低于对照组的138.00±10.5g/L(F=37.71,P<0.01);而SF分别为530.5±381.91 ng/ml和807.44±543.1 ng/ml,均明显高于对照组的104.06±112.2 ng/ml(F=14.10,P<0.01)。③51例研究对象的Hb与SF,Hepc及sTRAIL水平均呈负相关(r=-0.487,-0.379和-0.308,均P<0.05)。④SF与Hepc和sTRAIL呈正相关(r=0.350,0.544,均P<0.01),sTRAIL与Hepc呈正相关(r=0.321,P<0.05)。结论肿瘤及血液病患者血清sTRAIL高表达,sTRAIL与Hepc和IL-6均呈正相关。sTRAIL对肿瘤和血液病患者的Hb水平有负调控作用。Objective To researchthe expression characteristic of the serum sTRAIL and its correlation with the expression of serum IL-6 andhepcidin in patients with tumor and hematological diseases.Methods 18 tumor patients,16 hematological diseases patients and 17 healthy volunteers were recruited,and were measured the level of Hb,SF,IL-6,hepcidin and sTRAIL of them by ELISA,and then analysed the expression characteristic,correlation and clinical significance.Results①The serum levels of sTRAIL in tumor and hematological diseases group were 357.97±101.9pg/ml and 297.44±78.7pg/ml respectively,which were higher than 150.74±43.1pg/ml in control group(F=31.53,P<0.01).Hepcidin were 61.16±19.6μg/L and 67.54±19.5μg/L respectively,which were higher than 34.78±11.9μg/L in control group(F=16.74,P<0.01).IL-6 were 4.60±3.14mg/ml and 12.49±11.69mg/ml respectively,which were higher than1.66±0.28mg/ml in control group(F=5.69,P<0.01).②The Hb levels in tumor and hematological diseases group were 112.72±20.4g/L and 76.31±27.4g/L respectively,which were significantly lower than 138.00±10.5g/L of the control group(F=37.71,P<0.01).The levels of serum SF in tumor and hematological diseases group were 530.5±381.91 ng/ml and 807.44±543.1 ng/ml,which were higher than 104.06±112.2 ng/ml of the control group(F=14.10,P<0.01).③For 51 participants,Hb levels were a negative correlation with SF,Hepcidin and sTRAIL(respectively r=-0.487,-0.379 and-0.308,all P<0.05).④SF were positive related to Hepcidin and sTRAIL(r=0.350 and 0.544 respectively,all P<0.01),and hepcidin was positive correlated to sTRAIL(r=0.311,P<0.05).Conclusion sTRAIL were significantly increased in tumor and hematological patients,sTRAIL was positive related tohepcidin and IL-6.sTRAIL had certain relevance with Hepcidin and anemia pathogenesis.

关 键 词：肿瘤 血液病 可溶性肿瘤坏死因子相关凋亡诱导配体 白介素-6 铁调素 

分 类 号：R730.43[医药卫生—肿瘤]